Mesenchymal Cell News 10.25 June 26, 2018 | |
| |
TOP STORYInhibition of MicroRNA-138 Enhances Bone Formation in Multiple Myeloma Bone Marrow Niche Researchers showed that expression of miR-138 was significantly increased in MSCs from multiple myeloma patients and myeloma cells compared to those from healthy subjects. [Leukemia] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)IN VITROInvestigators established mouse clonal skeletal progenitors with distinct differentiation properties and analyzed their transcriptome. Unipotent osteogenic and adipogenic cells expressed specific transcriptional programs, whereas bipotent clones combined expression of those genes and did not show a unique signature. [Stem Cell Reports] Full Article | Graphical Abstract The authors seeded bone marrow-derived MSCS on the nanofibrous poly(l-lactic acid) scaffold with or without matrilin-3 (MATN3). They found that MATN3 suppressed hypertrophy in this 3D culture system in vitro. [Acta Biomater] Abstract | Graphical Abstract Scientists used label-free, non-invasive multiphoton microscopy to characterize bacterial nanocellulose – a promising biomaterial for bone tissue engineering – and their potency to stimulate collagen-I formation by MSCs. [Sci Rep] Full Article Cdc42 activity in undifferentiated human adipose-derived MSCs showed an age-dependent significant increase in Cdc42-GTP correlated to a decrease in Cdc42GAP; the low potentials of cell proliferation, doubling, adherence, and immunomodulatory ability contrary to the apoptotic index of the aged group were significantly reversed by ML141. [Stem Cell Res Ther] Full Article Gelatin-Based Microribbon Hydrogels Accelerate Cartilage Formation by Mesenchymal Stem Cells in 3D Compared to conventional hydrogels, macroporous gelatin-based microribbon scaffolds significantly increased the total amount of neocartilage produced by MSCs in 3D, with improved interconnectivity and mechanical strength. [Tissue Eng Part A] Abstract The authors documented through the analysis of a panel of human adipose-derived stem cells, that zinc finger protein 521 (ZNF521) strongly inhibited the generation of mature adipocytes. Enforced overexpression of ZNF521 in these cells resulted in a significant delay and reduction in adipocyte differentiation upon exposure to inducers of adipogenesis. [Stem Cell Rev] Abstract Researchers investigated the role of inhibin‐α on BMP9‐induced osteogenic differentiation in MSCs and tried to discover the mechanism underlying this process. They found that inhibin‐α apparently reduced the classical osteogenic markers and the ectopic bone formation induced by BMP9. [J Cell Biochem] Abstract IN VIVOMSC transplantation inhibited multiple parameters of spinal neuroinflammation found in diabetic mice, causing the reduction of activated astrocytes and microglia, oxidative stress signals, galectin-3, IL-1β, and TNF-α production. [J Neuroinflammation] Full Article The authors explored the role of fibrin glue-aided, instant epicardial placement to enhance the efficacy of MSC-based therapy in a rat ischemic cardiomyopathy model. [Sci Rep] Full Article Investigators examined the biodistribution and the efficacy of intraperitoneal luciferase-expressing human expanded adipose-derived stem cells (Luci-eASCs) in a mouse model of colitis. Luci-eASC-infused mice were stratified according to their response to the Luci-eASC treatment. [Int J Mol Sci] Full Article Subscribe to one of our other 19 science newsletters such as ESC & iPSC News & Cell Therapy News. | |
| |
REVIEWSThe authors present a concise review of the published data regarding the influence of various classes of chemotherapeutic agents on the survival, stem cell characteristics and physiological functions of MSCs. Molecular mechanisms underlying the effects are outlined, and resulting challenges of MSC‐based treatments for chemotherapy‐induced tissue injuries are discussed. [Int J Cancer] Abstract Visit our reviews page to see a complete list of reviews in the mesenchymal cell research field. | |
| |
SCIENCE NEWSKey Day 100 Survival Outcomes of Phase III Trial for Acute Graft versus Host Disease Presented Mesoblast Limited announced key Day 100 survival outcomes of its Phase III trial for remestemcel-L, an allogeneic MSC product candidate, in children with steroid refractory acute graft versus host disease. [Press release from Mesoblast Limited (GlobeNewswire, Inc.) discussing research presented at the International Society for Stem Cell Research (ISSCR) Annual Meeting, Melbourne] Press Release | |
| |
INDUSTRY NEWSSparta Systems, Inc. announced it is partnering with SurgaColl™ Technologies, an innovative medical device company supplying novel orthobiologics products for the surgical treatment of disease and regeneration of bone and cartilage tissues. [Sparta Systems, Inc.] Press Release NuVasive Launches AttraX Scaffold Biologic and Reports First Clinical Use NuVasive, Inc. announced the U.S. launch of AttraX® Scaffold, an absorbent ceramic-collagen bone graft with an optimized surface that has been validated in preclinical testing to drive increased bone formation and faster fusion than traditional ceramic bone grafts. The AttraX surface technology, through its carefully defined and tightly controlled features at the submicron scale, drives the differentiation of MSCs into bone-forming osteoblasts without added growth factors. [NuVasive, Inc.] Press Release Cynata Reports Positive 28-Day Data from Cohort B of Phase I Trial of CYP-001 in GvHD Cynata Therapeutics Limited announced positive safety and efficacy data from a day 28 analysis of patients in Cohort B of its Phase I clinical trial of CYP-001, the company’s lead Cymerus™ MSC product candidate, in steroid-resistant acute graft versus host disease (GvHD). [Cynata Therapeutics Limited] Press Release | |
| |
POLICY NEWSThe European country’s autocratic government has made a disturbing grab at the nation’s scientific institutions. [Nature News] Editorial Senate Panel Proposes $2 Billion, 5.4% Increase for NIH A U.S. Senate appropriations subcommittee approved a spending bill that calls for giving the National Institutes of Health (NIH) a $2 billion, 5.4% increase to $39.1 billion in the 2019 fiscal year that begins 1 October. [ScienceInsider] Editorial White House Proposes a Narrowing of FDA’s Mission — And a New Name The Trump administration has proposed a fundamental change to the mission of the FDA, one that would transfer most of the responsibility for regulating food safety to the Department of Agriculture and rename the FDA the “Federal Drug Administration”. [STAT News] Editorial US–Chinese Trade War Puts Scientists in the Cross Hairs Scientific research in the United States could become collateral damage in the country’s escalating trade dispute with China. Both countries went head-to-head in mid-June over tariffs on a long list of goods that includes lab equipment and reagents. That is likely to increase the cost of scientific research, and the impact could be felt more keenly in US labs. [Nature News] Editorial
| |
EVENTSNEW 2018 Till & McCulloch Meetings (TMM2018) Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESResearch Fellow – Stem Cell Biology and Engineering (New York Blood Center) Research Assistant – Cell Culture and Engineering (University of Oxford) Research Associate – Advanced Cell Culture Biology (The University of Manchester) Experimental Postdoctoral Position – Single-Cell Functional Genomics (Heidelberg University) Postdoctoral Researcher – Stem Cell Based Regenerative Medicine (Karolinska Institutet) Postdoctoral Positions – Cell Biology (Children’s Hospital of Philadelphia) Postdoctoral Research Assistant – Cell Biology (University of Oxford) Postdoctoral Position – Cell Biology (University of Houston) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mesenchymal Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|